News | October 17, 2023
Piramal Pharma launches in-vitro biology capabilities at Ahmedabad discovery services site
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Subscribe To Our Newsletter & Stay Updated
